Two growing biotechs blasted…
Two growing biotechs blasted through their IPO expectations Friday, with [...]
BioMarin Pharmaceutical has ended…
BioMarin Pharmaceutical has ended development of BMN 401 in all [...]
After a six-month wait, BioNTech…
After a six-month wait, BioNTech has finally filled its vacant [...]
Following a string of clinical…
Following a string of clinical setbacks, Vistagen’s nasal spray for [...]
Tarsus Pharmaceuticals is fronting…
Tarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals [...]
BioVie has hailed phase 2 data as…
BioVie has hailed phase 2 data as evidence that bezisterim [...]
Context Therapeutics has stopped…
Context Therapeutics has stopped development of the bispecific T-cell engager [...]
Actimed Therapeutics has brought…
Actimed Therapeutics has brought the full rights to its wasting [...]
Braveheart Bio has overcome its…
Braveheart Bio has overcome its own IPO expectations, rallying $382.5 [...]
Eli Lilly has axed another trial…
Eli Lilly has axed another trial of a gene therapy [...]